← Drug-vs-drug verdicts

Wegovy vs Ozempic (2026): Same Semaglutide, Different Labels

Wegovy (semaglutide, Novo Nordisk) vs Ozempic (semaglutide, Novo Nordisk)

Last verified 2026-05-27

The verdict

Wegovy and Ozempic are pharmacologically identical — both are once-weekly subcutaneous semaglutide manufactured by Novo Nordisk. The split is regulatory: Wegovy carries the FDA labels for chronic weight management (STEP-1) and cardiovascular risk reduction in obesity (SELECT), with a 2.4 mg max dose. Ozempic carries the type 2 diabetes label and CV risk reduction in T2D (SUSTAIN-6), capped at 2 mg. The right brand depends on the indication your insurance will cover.

Side-by-side comparison

FieldWegovyOzempic
Active ingredientSemaglutideSemaglutide
FDA-labeled indicationChronic weight management; CV risk reduction in obesity (Mar 2024)Type 2 diabetes; CV risk reduction in T2D + established CVD
Max labeled dose2.4 mg once weekly2.0 mg once weekly
Pivotal weight-loss trial−14.9% TBWL / 68 wk (STEP-1, 2.4 mg)−6.2% TBWL / 68 wk (STEP-2, 1.0 mg in T2D)
MechanismGLP-1 receptor agonistGLP-1 receptor agonist
Cardiovascular outcome trialMACE −20% in obesity without diabetes (SELECT, 2023)MACE −26% in T2D + high CV risk (SUSTAIN-6, 2016)
Cash price (manufacturer direct)$349 first 2 mo / $499 maintenance via NovoCareNo manufacturer cash-pay program; savings card commercial-T2D only
Commercial insurance PA criteriaBMI ≥30 (or ≥27 + comorbidity); obesity benefit (often excluded)A1c ≥6.5% + metformin trial; T2D benefit (broadly covered)

Frequently asked questions

Are Wegovy and Ozempic the same drug?

Yes. Both are semaglutide manufactured by Novo Nordisk — the identical molecule and identical once-weekly subcutaneous injection. Novo registered the same active ingredient under two brand names so each carries a distinct FDA-labeled indication and dose range: Wegovy for chronic weight management (titrated up to 2.4 mg, approved Jun 2021) and Ozempic for type 2 diabetes (capped at 2 mg, approved Dec 2017). Pharmacologically interchangeable at overlapping doses (0.25 – 2 mg).

Can I get Wegovy if I have type 2 diabetes?

Yes. Wegovy is FDA-approved for adults with obesity or overweight + a weight-related comorbidity, and type 2 diabetes qualifies as a comorbidity. STEP-2 (Davies 2021 Lancet, PMID 33667417) specifically studied semaglutide 2.4 mg in 1,210 adults with overweight/obesity and T2D, showing −6.2% body weight at 68 weeks. The label indication is weight management, not glycemic control — some plans require a separate Ozempic prescription if A1c control is the goal.

Why does my doctor switch me from Ozempic to Wegovy?

Because Ozempic caps at 2 mg per week, while Wegovy titrates up to 2.4 mg per week — the dose used in the STEP weight-loss trials. Patients who plateau at Ozempic 2 mg and need additional weight loss must move to Wegovy to reach the 2.4 mg target. The molecule is identical, so most clinicians transition directly from Ozempic 2 mg to Wegovy 1.7 mg or 2.4 mg without a fresh titration restart, though insurance authorization shifts from a T2D criterion to an obesity criterion.

Which is covered by insurance for weight loss?

Wegovy. It carries the FDA chronic weight management indication, so plans that include an obesity benefit will cover it (typically BMI ≥30 or ≥27 + comorbidity, plus documented lifestyle attempts). Ozempic is FDA-approved only for type 2 diabetes — prescribing it for weight loss without T2D is off-label and rarely reimbursed. Roughly 40% of commercial plans exclude obesity drugs entirely, leaving Wegovy patients on the NovoCare $349 – $499/mo direct-pay tier.

What's the dose difference between Wegovy and Ozempic?

Wegovy titrates through 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly (5 steps, 4 weeks each). Ozempic titrates 0.25 → 0.5 → 1.0 → 2.0 mg weekly (4 steps). The 2.4 mg Wegovy maintenance dose is the highest semaglutide exposure available and is the dose tested in STEP-1 (−14.9% body weight) and SELECT (MACE −20%). Ozempic 2 mg is the highest dose approved for T2D, based on SUSTAIN FORTE.

Which has stronger cardiovascular evidence?

Both have proven CV benefit, in different populations. SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186) showed semaglutide cut MACE 26% (HR 0.74) in 3,297 patients with type 2 diabetes and high CV risk — the basis for Ozempic's CV indication. SELECT (Lincoff 2023 NEJM, PMID 37952131) showed semaglutide 2.4 mg cut MACE 20% (HR 0.80) in 17,604 adults with obesity and established CVD but no diabetes — the basis for Wegovy's CV indication added in March 2024.

References

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  2. 2.Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PMID: 33667417.
  3. 3.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. PMID: 27633186.
  4. 4.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  5. 5.Novo Nordisk. WEGOVY (semaglutide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  6. 6.Novo Nordisk. OZEMPIC (semaglutide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  7. 7.Novo Nordisk. NovoCare direct-pay pricing for Wegovy — $349 first 2 months / $499 maintenance. NovoCare. 2026. https://www.novocare.com/wegovy/let-us-help/savings-offer.html

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.